-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Deck Pharmaceuticals recently announced that the National Medical Products Administration (NMPA) has accepted the world's first oral XPO1 inhibitor selinexor in a phase II clinical trial of monotherapy for patients with myelofibrosis (MF) in China
The trial is a phase II, randomized, open-label, multi-center clinical study that evaluates the safety of Celinisole compared with doctor-chosen (PC) treatment in MF patients who have been treated with JAK1/2 inhibitors for at least 6 months Sex and efficacy